Iovance Biotherapeutics, Inc. (IOVA)
14.72
+0.51
(+3.59%)
USD |
NASDAQ |
Oct 15, 16:00
14.70
-0.02
(-0.14%)
After-Hours: 20:00
Iovance Biotherapeutics Cash from Operations (TTM) : -264.18M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -264.18M |
| March 31, 2026 | -270.79M |
| December 31, 2025 | -302.41M |
| September 30, 2025 | -323.14M |
| June 30, 2025 | -303.41M |
| March 31, 2025 | -334.39M |
| December 31, 2024 | -352.98M |
| September 30, 2024 | -363.65M |
| June 30, 2024 | -388.76M |
| March 31, 2024 | -384.28M |
| December 31, 2023 | -361.82M |
| September 30, 2023 | -355.52M |
| June 30, 2023 | -335.09M |
| March 31, 2023 | -318.77M |
| December 31, 2022 | -292.76M |
| September 30, 2022 | -268.94M |
| June 30, 2022 | -262.98M |
| March 31, 2022 | -239.35M |
| December 31, 2021 | -227.94M |
| September 30, 2021 | -236.78M |
| June 30, 2021 | -219.61M |
| March 31, 2021 | -202.23M |
| December 31, 2020 | -205.13M |
| September 30, 2020 | -196.26M |
| June 30, 2020 | -197.93M |
| Date | Value |
|---|---|
| March 31, 2020 | -195.09M |
| December 31, 2019 | -158.89M |
| September 30, 2019 | -136.62M |
| June 30, 2019 | -122.36M |
| March 31, 2019 | -112.49M |
| December 31, 2018 | -101.25M |
| September 30, 2018 | -90.66M |
| June 30, 2018 | -84.18M |
| March 31, 2018 | -77.76M |
| December 31, 2017 | -78.71M |
| September 30, 2017 | -69.90M |
| June 30, 2017 | -60.67M |
| March 31, 2017 | -46.92M |
| December 31, 2016 | -32.67M |
| September 30, 2016 | -27.09M |
| June 30, 2016 | -18.72M |
| March 31, 2016 | -19.47M |
| December 31, 2015 | -18.38M |
| September 30, 2015 | -15.12M |
| June 30, 2015 | -13.00M |
| March 31, 2015 | -9.824M |
| December 31, 2014 | -8.633M |
| September 30, 2014 | -7.572M |
| June 30, 2014 | -6.270M |
| March 31, 2014 | -5.630M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| AVITA Medical, Inc. | -24.71M |
| Halozyme Therapeutics, Inc. | 818.60M |
| Amgen, Inc. | 12.48B |
| CareDx, Inc. | 93.66M |
| Xencor, Inc. | -205.81M |